Esters of 4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazineethanol and related compounds as long-acting antipsychotic agents. Synthesis of the 1-adamantoate, the first crystalline base. 4

1977 ◽  
Vol 20 (2) ◽  
pp. 302-304 ◽  
Author(s):  
Harry L. Yale
Keyword(s):  
Antipsychotic Agents ◽  
Crystalline Base ◽  
Long Acting ◽  
Related Compounds

Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

2004 ◽  
Vol 16 (6) ◽  
pp. 319-325 ◽  
Author(s):  
Pierre S. Chue ◽  
Peter D'Hoore ◽  
J. Michael Ramstack
Keyword(s):  
Antipsychotic Agents ◽  
Term Treatment ◽  
Treatment Programs ◽  
Sustained Drug Delivery ◽  
Partial Compliance ◽  
Long Term Treatment ◽  
Optimal Maintenance ◽  
Long Acting ◽  
The Impact

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical class. Atypical agents which are given orally have been shown to provide long-term efficacy and tolerability benefits compared with conventional agents, but are limited by the need for daily administration. The most recent pharmacological strategy to achieve optimal maintenance treatment has been to combine the benefits of an atypical antipsychotic with delivery in a water-based long-acting formulation. The first antipsychotic to achieve this combination – long-acting risperidone – may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

2005 ◽  
Vol 23 (S1) ◽  
pp. 75-89 ◽  
Author(s):  
Natalie Christine Edwards ◽  
Julie C. Locklear ◽  
Marcia F. T. Rupnow ◽  
Ronald J. Diamond
Keyword(s):  
Cost Effectiveness ◽  
Antipsychotic Agents ◽  
The Usa ◽  
Long Acting

scholarly journals Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report

2018 ◽  
Vol 18 (2) ◽  
pp. 208 ◽  
Author(s):  
Hassan Mirza ◽  
Duncan Harding ◽  
Naser Al-Balushi
Keyword(s):  
Case Report ◽  
Early Adulthood ◽  
Antipsychotic Agents ◽  
Acute Onset ◽  
Paliperidone Palmitate ◽  
Adolescent Male ◽  
Psychotic Symptoms ◽  
National Health Service Foundation ◽  
Oral Medications ◽  
Long Acting

Schizophrenia is a serious long-term mental disorder which usually presents in adolescence or early adulthood. However, poor adherence to oral antipsychotics can lead to relapse and rehospitalisation. We report an adolescent male with schizophrenia who was referred to the South London & Maudsley National Health Service Foundation Trust, London, UK, in 2015 due to worsening psychotic symptoms. Following poor compliance with oral medications, a four-week regimen of paliperidone palmitate long-acting injections was initiated, with an initial positive response. However, 10 days after the second dose, the patient developed severe acute-onset delirium with fluctuating levels of consciousness. Paliperidone palmitate was discontinued and the patient instead underwent a course of zuclopenthixol decanoate long-acting injections with a favourable outcome.Keywords: Adolescent Psychiatry; Schizophrenia; Antipsychotic Agents; Delirium; Paliperidone Palmitate; Zuclopenthixol; Case Report; United Kingdom.

Long-acting injectable antipsychotic agents

1979 ◽  
Vol 17 (11) ◽  
pp. 41-43
Keyword(s):  
Antipsychotic Agents ◽  
Fluphenazine Decanoate ◽  
Fluphenazine Enanthate ◽  
Long Acting ◽  
Flupenthixol Decanoate

Five long-acting injectable antipsychotic agents (neuroleptics) are available. They are fluphenazine enanthate (Moditen enanthate),1 fluphenazine decanoate (Modecate),2 flupenthixol decanoate (Depixol), cis-clopenthixol decanoate (Clopixol) and fluspirilene (Redeptin).3 Their therapeutic and unwanted effects are broadly similar to those of their oral forms. Nevertheless, injectable preparations have distinct advantages as well as problems.

Sign in / Sign up

Export Citation Format

Share Document